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THERE is a great deal of indirect
evidence that the ovaries are involved in
the aetiology of breast cancer. Thus
normal ovarian function and pregnancy
are considered to exert some protective
effect against the development of breast
tumours (Lowe and MacMahon, 1970).
In contrast, sterile women have a higher
risk factor and anovulation is present in a
large number of patients with the estab-
lished disease (Grattarola, 1964).
Furthermore, ovarian dysfunction in
patients with breast cancer is often
accompanied by endometrial hyperplasia
and marked increases in the level of
urinary testosterone (Grattarola, 1967,
1969). It has also been shown that these
patients have significantly higher levels of
the metabolite than women with endo-
metrial hyperplasia alone-both before
and after the menopause (Grattarola,
1967, 1970; Grattarola et al., 1974). It
was postulatedthatthe increased androgen
production probably originated from the
ovaries. This claim is supported by the
finding of interstitial-cell hyperplasia
(Hall and Dederiel, 1959), and the conclu-
sion that this ovarian compartment is
concerned primarily with the production
of Clg-steroids (Rice and Savard, 1966;
Mattingley and Huang, 1969).
The aim of the present study was to
obtain further information on the concen-
tration of testosterone glucuronide in
Accepted 17 January 1977
urine from matched groups of women
with either benign or malignant tumours
of the breast.
Eighty-ninepatients (aged 25-70years)
were studied after being admitted to hos-
pital for breast surgery. All gave their
informed consent. After the tissue had
been removed the women were divided
into two groups depending on whether
the tumour was benign or malignant
according to the histology report. Only
patients with cancer Stages I and II ofthe
Manchester classification (Wise, York
Mason and Ackerman, 1971) were included
in the group with malignancies. The
subjects were then categorized as being
either pre- or postmenopausal, depend-
ing on whether 6 months or more had
elapsed since the last menstrual period.
The menopausal status of every subject
was checked 2 years later, and if any
doubt existed about their original classi-
fication, these patients were excluded from
the study. Similarly, patients on drugs
likely to affect androgen metabolism were
not included in the investigation.
Urine samples were collected for 24 h
from every patient from Days 3 to 2 prior
to the operation. The concentration of
testosterone glucuronide was measured
directly by radioimmunoassay without
hydrolysis or extraction. Fifty pl of
urine was dried at 100°C to eliminate
non-specific binding by urinary proteins.
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The residues were cooled, resdissolved in
buffer and equilibrated with antiserum
to testosterone-17p-glucosiduronyl-bovine
serum albumin and tritiated testosterone
glucuronide. The unbound steroid was
removed with dextran-coated charcoal.
The method has been described and
evaluated in detail (Hennam, Collins and
Sommerville, 1973). The phase of the
menstrual cycle was not taken into con-
sideration in those women who still had
menses, because the fluctuations in the
amount of metabolite excreted are small
and the pattern is variable (Collins and
Hennam, 1976).
The frequencies with which various
concentrations of testosterone glucuronide
appeared in each group were studied, and
it was concluded that comparisons were
best carried out using a non-parametric
method, viz: the Mann-Whitney U Test.
The results are shown in the Table.
TABLE. The Concentration (nmol/24 h) of
Testosterone Glucuronide in Urine from
Women with Benign or Early Malignant
Disease of the Breast.
No. of
Source subjects Median Range
Premenopausal
Benign 40 48-42 15-61-110-06
Cancer 16 46-91 8-77-119*03
Postmenopausal
Benign 8 34-08 17*46-87*95
Cancer 25 31-31 17-26-98*31
There were no significant differences
in the concentration of testosterone glucu-
ronide in samples from patients with
benign or malignant breast disease-
either before or after the menopause.
Thisfindingis inagreementwithaprevious
study on the concentration of testosterone
in peripheral venous plasma from the
same groups of subjects (Jones et al.,
1977). The results, however, do not
concur with those of Grattarola, who
measured total urinary testosterone by
gas-liquid chromatography, in patients
with early cancer of the breast, and found
higher values than in a healthy control
group (Grattarola, 1967, 1970, 1973;
Grattarola et al., 1974). Accordingly, our
data do not support the rationale for
offering ovarian ablation therapy to post-
menopausal patients with breast cancer,
when increased androgen production is
proven (Hall and Dederiel, 1959), neither
does it help to explain the claim that early
oophorectomy significantly reduces the
incidence of breast cancer (Feinleib, 1968)
There is, however, much evidence of
disturbed androgen metabolism in women
with breast cancer. For example, there
is a decreased level of androsterone and
aetiocholanone in urine (Hayward and
Bulbrook, 1968; Bulbrook, Hayward and
Spicer, 1971). These metabolites are
derived from circulating dehydroepiandro-
sterone sulphate, dehydroepiandro-
sterone and androstenedione, and are
thus primarily of adrenal origin. In
addition, there is an increased production
of sebum by the sebaceous glands, which
are androgen-sensitive (Burton, Cunliffe
and Schuster, 1970). Testosterone glucu-
ronide in urine is derived from circulating
testosterone (,-0.1%), androstenedione
(0.4%) and dehydroepiandrosterone
(0.003%). It is thus of adrenal and
ovarian origin, and is a more informative
index concerning the production of andro-
gens, according to the standard definition
(Sommerville and Collins, 1970). Thus
the findings to date suggest that it is the
weaker androgens of adrenal origin that
are more concerned in the aetiology of
breast cancer, or perhaps it is small
differences in the level of biologically
active androgen at the level of the
responsive tissue. It is apparent that
more detailed information is required on
androgen metabolism in these patients.
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